Advertisement

Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward

      In response to an ongoing nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) epidemic, and in anticipation of a continuous increase of its prevalence in the near future, the American Gastroenterological Association (AGA) together with the Endocrine Society, the American Association of Clinical Endocrinologists (AACE) and other outstanding medical associations organized last summer a virtual conference of international experts in gastroenterology, endocrinology and primary care, and initiated an ongoing collaborative project, in the context of the ‘Call to Action Meeting’ [
      • Kanwal F.
      • Shubrook J.H.
      • Younossi Z.
      • Natarajan Y.
      • Bugianesi E.
      • Rinella M.
      • et al.
      Preparing for the NASH epidemic: a call to action.
      ]. Kanwal et al. are reporting in a paper published in this issue of “Metabolism”, and at the same time in “Gastroenterology”, the proposed action plan to improve the diagnosis and management of the disease [
      • Kanwal F.
      • Shubrook J.H.
      • Younossi Z.
      • Natarajan Y.
      • Bugianesi E.
      • Rinella M.
      • et al.
      Preparing for the NASH epidemic: a call to action.
      ]. The same consortium of professional Societies is going to issue clinical recommendations and guidelines for the preventive care, diagnosis, and management of NASH very soon. It is noteworthy that a similar initiative has not yet occurred elsewhere outside the USA, although it is our expectation that this initial effort may eventually be expanded internationally.

      Abbreviations:

      CV (cardiovascular), CVS (cardiovascular disease), MetS (metabolic syndrome), NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kanwal F.
        • Shubrook J.H.
        • Younossi Z.
        • Natarajan Y.
        • Bugianesi E.
        • Rinella M.
        • et al.
        Preparing for the NASH epidemic: a call to action.
        Metabolism. 2021;
        • Long M.T.
        • Gandhi S.
        • Loomba R.
        Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.
        Metabolism. 2020; 111S: 154259https://doi.org/10.1016/j.metabol.2020.154259
        • Singh A.
        • Dhaliwal A.S.
        • Singh S.
        • Kumar A.
        • Lopez R.
        • Gupta M.
        • et al.
        Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort.
        Dig Dis Sci. 2020; 65: 978-986https://doi.org/10.1007/s10620-019-05700-9
        • Katsiki N.
        • Mikhailidis D.P.
        • Mantzoros C.
        Non-alcoholic fatty liver disease and colorectal cancer: a marker of risk or common causation?.
        Metabolism. 2018; 87: A10-A13https://doi.org/10.1016/j.metabol.2018.08.003
        • Mantovani A.
        • Dauriz M.
        • Byrne C.D.
        • Lonardo A.
        • Zoppini G.
        • Bonora E.
        • et al.
        Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.
        Metabolism. 2018; 87: 1-12https://doi.org/10.1016/j.metabol.2018.06.004
        • Polyzos S.A.
        • Mantzoros C.S.
        Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).
        Metabolism. 2020; 111: 154318https://doi.org/10.1016/j.metabol.2020.154318
        • Kechagias S.
        • Nasr P.
        • Blomdahl J.
        • Ekstedt M.
        Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.
        Metabolism. 2020; 111S: 154183https://doi.org/10.1016/j.metabol.2020.154183
        • Polyzos S.A.
        • Kountouras J.
        • Mantzoros C.S.
        Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics.
        Metabolism. 2019; 92: 82-97https://doi.org/10.1016/j.metabol.2018.11.014
        • Perakakis N.
        • Stefanakis K.
        • Mantzoros C.S.
        The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
        Metabolism. 2020; 111S: 154320https://doi.org/10.1016/j.metabol.2020.154320
        • Perakakis N.
        • Polyzos S.A.
        • Yazdani A.
        • Sala-Vila A.
        • Kountouras J.
        • Anastasilakis A.D.
        • et al.
        Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.
        Metabolism. 2019; 101: 154005https://doi.org/10.1016/j.metabol.2019.154005
        • Polyzos S.A.
        • Mantzoros C.S.
        Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.
        Metabolism. 2014; 63: 161-167https://doi.org/10.1016/j.metabol.2013.10.010
        • Stefan N.
        • Häring H.U.
        • Cusi K.
        Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
        Lancet Diabetes Endocrinol. 2019; 7: 313-324https://doi.org/10.1016/S2213-8587(18)30154-2
        • Polyzos S.A.
        • Kountouras J.
        • Anastasiadis S.
        • Doulberis M.
        • Katsinelos P.
        Nonalcoholic fatty liver disease: is it time for combination treatment and a diabetes-like approach?.
        Hepatology. 2018; 68: 389https://doi.org/10.1002/hep.29897
        • Polyzos S.A.
        • Kountouras J.
        • Zavos C.
        • Deretzi G.
        Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.
        J Clin Gastroenterol. 2012; 46: 272-284https://doi.org/10.1097/MCG.0b013e31824587e0
        • Romero-Gómez M.
        • Zelber-Sagi S.
        • Trenell M.
        Treatment of NAFLD with diet, physical activity and exercise.
        J Hepatol. 2017; 67: 829-846https://doi.org/10.1016/j.jhep.2017.05.016
        • Muzurović E.
        • Mikhailidis D.P.
        • Mantzoros C.
        Commentary: from mice to men: in search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based.
        Metabolism. 2020; 109154305https://doi.org/10.1016/j.metabol.2020.154305
        • European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)
        EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.
        J Hepatol. 2016; 64: 1388-1402https://doi.org/10.1016/j.jhep.2015.11.004
        • Fan J.G.
        • Wei L.
        • Zhuang H.
        • Cai W.
        • Feng Chen D.
        • Duan Z.P.
        • et al.
        Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
        J Dig Dis. 2019; 20: 163-173https://doi.org/10.1111/1751-2980.12685
        • Nudel J.
        • Sanchez V.M.
        Surgical management of obesity.
        Metabolism. 2019; 92: 206-216https://doi.org/10.1016/j.metabol.2018.12.002
        • Boutari C.
        • Polyzos S.A.
        • Mantzoros C.S.
        Of mice and men: why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?.
        Metabolism. 2019; 96https://doi.org/10.1016/j.metabol.2019.03.007
        • Polyzos S.A.
        • Kang E.S.
        • Tsochatzis E.A.
        • Kechagias S.
        • Ekstedt M.
        • Xanthakos S.
        • et al.
        Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.
        Metabolism. 2020; 113: 154413https://doi.org/10.1016/j.metabol.2020.154413
        • Polyzos S.A.
        • Kang E.S.
        • Boutari C.
        • Rhee E.J.
        • Mantzoros C.S.
        Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
        Metabolism. 2020; 111S: 154203https://doi.org/10.1016/j.metabol.2020.154203
        • Mantovani A.
        • Scorletti E.
        • Mosca A.
        • Alisi A.
        • Byrne C.D.
        • Targher G.
        Complications, morbidity and mortality of nonalcoholic fatty liver disease.
        Metabolism. 2020; 111S: 154170https://doi.org/10.1016/j.metabol.2020.154170